Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01684943 · ClinicalTrials.gov registry record · NA
Selecting Insulin Analogs for Closed-Loop Control Using Multiplex Pharmacokinetic Profiling
A NA study of Type 1 Diabetes, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT01684943: Completed NA study of Type 1 Diabetes, sponsored by Massachusetts General Hospital.
NCT01684943 is a NA study of Type 1 Diabetes that has completed, run by Massachusetts General Hospital. The registered enrollment target is 33 participants, below the 767-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01684943, a NA study of Type 1 Diabetes, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators are doing this research study to compare the pharmacokinetics (PK) (rate of absorption) of insulin lispro (Humalog), insulin aspart (Novolog), and insulin glulisine (Apidra) within individual subjects. Additionally, the investigators will perform a preliminary feasibility evaluation of a minimally invasive continuous insulin monitoring (CIM) device and its use to derive PK parameters in human subjects.
Primary Outcome
The average difference in tmax between lispro and aspart in all participants
Conditions Studied
Interventions
- OTHER Multiplex pharmacokinetic profiling
- OTHER Continuous insulin monitoring
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2010-07 |
| Est. Completion | 2017-12 |
| Phase | NA |
What the finished NCT01684943 record still lists
NCT01684943 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 767-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Multiplex pharmacokinetic profiling is the first listed.
NCT01684943 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01684943 about?
NCT01684943 is a clinical study titled "Selecting Insulin Analogs for Closed-Loop Control Using Multiplex Pharmacokinetic Profiling". The investigators are doing this research study to compare the pharmacokinetics (PK) (rate of absorption) of insulin lispro (Humalog), insulin aspart (Novolog), and insulin glulisine (Apidra) within individual subjects. Additionally, the investigators will perform a preliminary feasibility evaluati...
What is the current status of trial NCT01684943?
This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2010-07. Estimated completion is 2017-12.
What conditions does trial NCT01684943 study?
This clinical trial studies the following conditions: Type 1 Diabetes.
What interventions are being tested in trial NCT01684943?
The interventions under investigation include: Multiplex pharmacokinetic profiling (OTHER), Continuous insulin monitoring (OTHER).
Who is sponsoring clinical trial NCT01684943?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01684943 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01684943's enrollment target sits among peer trials
33 121st of 198 higher than 76 of 198 other Type 1 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 1 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
REAL-Fam Feasibility Study for Youth Diabetes Management
RECRUITING · NA
-
AIDANET Pediatrics
RECRUITING · NA
-
A Study Comparing Dexcom Continuous Glucose Monitoring to Point of Care Glucose Testing for the Management of Hospital and Post-Discharge Subjects With Type 1 Diabetes
RECRUITING · NA
-
Safety and Feasibility of a Self-Learning Bolus Calculator With Simplified Meal Announcement in Adolescents With Type 1 Diabetes Using Automated Insulin Delivery
RECRUITING · NA
-
EMPoWER Study - Strengths-based Behavioral Intervention for Youth With Type 1 Diabetes
RECRUITING · NA
-
Safety and Feasibility of a Machine-Learning Bolus Priming Added to Existing Control Algorithm
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia